Mineralys Therapeutics Inc (NASDAQ: MLYS) kicked off on Friday, up 2.36% from the previous trading day, before settling in for the closing price of $36.05. Over the past 52 weeks, MLYS has traded in a range of $8.24-$47.65.
During the last 5-year period, the sales drop of Healthcare Sector giant was -170.42%. While this was happening, its average annual earnings per share was recorded 34.97%. With a float of $56.37 million, this company’s outstanding shares have now reached $78.97 million.
Mineralys Therapeutics Inc (MLYS) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Mineralys Therapeutics Inc is 28.77%, while institutional ownership is 79.50%. The most recent insider transaction that took place on Nov 20 ’25, was worth 43,350,000. In this transaction Director of this company sold 1,000,000 shares at a rate of $43.35, taking the stock ownership to the 7,903,838 shares. Before that another transaction happened on Nov 20 ’25, when Company’s Affiliate proposed sale 1,000,000 for $42.12, making the entire transaction worth $42,120,000.
Mineralys Therapeutics Inc (MLYS) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.98 earnings per share (EPS), higher than consensus estimate (set at -1.08) by 0.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.49 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.53% during the next five years compared to -170.42% drop over the previous five years of trading.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Take a look at Mineralys Therapeutics Inc’s (MLYS) current performance indicators. Last quarter, stock had a quick ratio of 25.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.96, a number that is poised to hit -0.51 in the next quarter and is forecasted to reach -2.27 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
Looking closely at Mineralys Therapeutics Inc (NASDAQ: MLYS), its last 5-days average volume was 1.58 million, which is a jump from its year-to-date volume of 1.19 million. As of the previous 9 days, the stock’s Stochastic %D was 10.50%.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 69.34%, which indicates a significant increase from 13.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.93 in the past 14 days, which was lower than the 2.14 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $40.90, while its 200-day Moving Average is $23.56. However, in the short run, Mineralys Therapeutics Inc’s stock first resistance to watch stands at $38.74. Second resistance stands at $40.59. The third major resistance level sits at $42.02. If the price goes on to break the first support level at $35.46, it is likely to go to the next support level at $34.03. Should the price break the second support level, the third support level stands at $32.18.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
The company with the Market Capitalisation of 2.92 billion has total of 79,140K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -177,810 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -36,930 K.
